SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is experiencing extreme volatility as investors weigh the company's strong revenue growth against a federal indictment involving co-founder Yih-Shyan Wally Liaw in an alleged AI chip smuggling scheme to China. While the company is not a named defendant and maintains it is cooperating with authorities, community sentiment remains sharply divided between those viewing the sell-off as a generational buying opportunity and others fearing long-term reputational damage and potential supply chain repercussions from Nvidia.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is trending as traders debate the impact of high-stakes geopolitical brinkmanship in the Middle East, specifically revolving around threats to the Strait of Hormuz and potential infrastructure strikes. The community is actively divided, with many debating whether the ongoing volatility represents a genuine long-term supply shock or a series of tactical market manipulations driven by official rhetoric.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors react to a major leadership overhaul, including the appointment of Kevin Tang as CEO, while the community anticipates potential strategic shifts and future buyout scenarios following recent institutional accumulation and aggressive insider buying. Shareholders remain focused on the company's Q4 earnings, actively debating the long-term impact of the management transition and the secretive development status of the pipeline candidate AUR-200.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing intense volatility as investors weigh stellar earnings and HBM demand against broader macroeconomic risks like escalating tensions in the Middle East. The community is deeply divided, with many labeling the sharp price decline as market manipulation while others treat the dip as a prime accumulation opportunity ahead of the stock's upcoming inclusion in the S&P 100.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors react to its recent NYSE listing, with the community actively debating the premium relative to net asset value and the impact of the six-month lock-up period on the tradable float. Traders are closely monitoring the fund's exposure to high-profile private AI and tech companies, fueling speculation about potential price volatility and long-term valuation.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

The community is actively debating the volatility of SCO as traders attempt to capitalize on shifting crude oil narratives amid geopolitical tensions in the Middle East. While many are focused on the potential for long-term gains if oil prices normalize, others are expressing frustration over the ETF's decay and its tendency to deviate from expected inverse performance during rapid market swings.

ProShares Trust - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

ProShares Ultra Bloomberg Crude Oil is trending as traders react to heightened geopolitical instability in the Middle East and concerns over the closure of the Strait of Hormuz. The community is actively debating the potential for long-term energy supply shocks, with polarized discussions focused on whether to capitalize on volatility through shorting or riding the momentum of rising crude prices.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors react to bipartisan legislative efforts targeting sports betting on CFTC-regulated prediction markets, which analysts view as a potential competitive win for established operators like DraftKings. Community discussion is heavily focused on the company's 'Super App' strategy, debates over market share impacts from prediction market rivals, and ongoing frustration regarding management's selling activity.

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.

Valneva SE - ADR

Valneva is currently in the spotlight as investors debate the potential regulatory path for its Lyme disease vaccine following a missed primary endpoint in a Phase 3 trial. While some in the community see the solid efficacy data as a strong basis for upcoming FDA submissions, others are expressing frustration over the lack of near-term catalysts and the resulting downward pressure on the stock.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Karyopharm Therapeutics is experiencing significant market volatility and intense community scrutiny as investors weigh the company's precarious cash runway against upcoming Phase 3 SENTRY clinical trial results. While some shareholders express deep frustration with management and persistent dilution concerns, bullish traders are actively positioning through complex options activity, speculating on a potential turnaround or strategic acquisition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Healthcare Equity ETF (GDOC) Hits Fresh 52-Week High 

GDOC hits a 52-week high as aging demographics, tech advances and strength from top holding LLY fuel momentum. 

MoonLake Immunotherapeutics, a clinical-stage biotech firm valued at $2.6 billion, is generating excitement with its experimental treatment for hidradenitis suppurativa (HS), a chronic and painful skin condition.&nbsp;On Friday, Goldman Sachs upgraded the stock to a&nbsp;'Buy' from&nbsp;'Neutral,' with analyst Richard Law raising the price target from $62 to $82 — an 85% upside from current levels, CNBC&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/01/17/this-little-known-biotech-stock-is-a-buy-thats-primed-to-double-in-price-goldman-says.html">reported</a>.While MoonLake is gaining traction among institutional investors, it remains underfollowed on Stocktwits, with fewer than 600 watchers.&nbsp;Over the past year, retail interest has been budding, with a 12% increase in followers, even as the stock has fallen 26%.Law reportedly believes MoonLake's experimental nanobody treatment, sonelokimab (SLK), holds transformative potential.&nbsp;SLK demonstrated impressive efficacy in phase 2 trials, leading to optimism about its success in phase 3.&nbsp;Additionally, SLK's inclusion of AbbVie's Skyrizi — currently the standard of care for psoriatic arthritis (PsA) — as a reference treatment offers a key differentiator, according to the analyst.Law suggests that while this adds some risk, the potential to position SLK as superior in a competitive market far outweighs the drawbacks.Goldman Sachs isn't alone in its optimism. Oppenheimer included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.&nbsp;The brokerage sees biotech equities as undervalued relative to other sectors, with strong catalysts like lower interest rates, robust M&amp;A prospects, and transformative data releases creating a favorable backdrop this year.MoonLake ended the third quarter (Q3) of 2024 with $493.9 million in cash, cash equivalents, and marketable securities, which the company said provides a runway through 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Over the past year, retail interest has been budding, with a 12% increase in followers, even as the stock has fallen 26%.

Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely?

Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.

GDOC
Goldman Sachs ETF Trust - Goldman Sachs Future Health Care Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Latest GDOC News

GDOCGoldman Sachs ETF Trust - Goldman Sachs Future Health Care Equity ETF